Amendments to pregnancy labeling
Executive Summary
A proposed rule to alter labeling concerning the use of prescription drugs in pregnancy is under review of the White House Office of Management and Budget as of Jan. 3. The proposal, titled "Content and Format of Labeling for Human Prescription Drugs and Biologics: Requirements for Pregnancy and Lactation Labeling," would revise labeling due to concerns expressed by stakeholders at a public hearing, in focus groups, and in several advisory committee meetings that the letter categories (A, B, C, D, X) currently used to characterize the risk to the fetus of using the drug during pregnancy are confusing, overly simplistic and not adequate to communicate risks effectively...
You may also be interested in...
Pregnancy labeling due date nears
A proposed regulation on the format and content of drug labeling to address pregnancy and lactation issues could be published this month, according to the HHS Semiannual Regulatory Agenda. Published in the May 5 Federal Register, the agenda sets a May 2008 target date for the proposed rule, which is intended to convey more clearly the risks to a fetus or newborn from a mother's use of a drug (1"The Pink Sheet," Jan. 7, 2008, In Brief)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.